Literature DB >> 7680352

Hyporeninemic normoaldosteronism in severe autonomic failure.

I Biaggioni1, F Garcia, T Inagami, V Haile.   

Abstract

Sympathetic mechanisms play an important role in the acute regulation of renin release in humans. On the other hand, the effect of chronic sympathetic deprivation on the renin-aldosterone system has not been fully evaluated. We, therefore, studied 24 patients with severe autonomic failure due to pure autonomic failure (n = 14) or to multiple system atrophy (n = 10). Supine plasma renin activity (PRA) was low (0.09 +/- 0.01 ng/(L*s)) and remained virtually unchanged in the upright posture (0.10 +/- 0.01 ng/(L*s)) despite profound orthostatic hypotension to levels that should activate renal baroreceptors. Isoproterenol, at doses that produced significant tachycardia and hypotension, also failed to stimulate PRA. Furthermore, renin-producing cells were absent in the kidneys of two autopsy cases. Norepinephrine depletion alone could not explain these findings because no correlation was found between plasma norepinephrine and PRA, and because PRA was normal in patients with intact sympathetic innervation but congenital absence of norepinephrine. In contrast, supine and upright plasma aldosterone were normal in autonomic failure patients (220 +/- 20 and 440 +/- 70 pmol/L). We speculate that direct sympathetic innervation is essential for the maintenance of renin, perhaps by providing trophic stimuli.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680352     DOI: 10.1210/jcem.76.3.7680352

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Nocturnal blood pressure dipping in the hypertension of autonomic failure.

Authors:  Luis E Okamoto; Alfredo Gamboa; Cyndya Shibao; Bonnie K Black; André Diedrich; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2008-12-01       Impact factor: 10.190

Review 2.  Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.

Authors:  Jacquie Baker; Kurt Kimpinski
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

Review 3.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.

Authors:  Italo Biaggioni
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

Review 4.  Management approaches to hypertension in autonomic failure.

Authors:  Amy C Arnold; Italo Biaggioni
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-09       Impact factor: 2.894

5.  Renal impairment of pure autonomic failure.

Authors:  Emily M Garland; Alfredo Gamboa; Luis Okamoto; Satish R Raj; Bonnie K Black; Thomas L Davis; Italo Biaggioni; David Robertson
Journal:  Hypertension       Date:  2009-09-08       Impact factor: 10.190

Review 6.  Cardiovascular complications in patients with autonomic failure.

Authors:  Valeria Milazzo; Cristina Di Stefano; Alberto Milan; Agnese Ravera; Gabriele Sobrero; Luca Sabia; Franco Veglio; Simona Maule
Journal:  Clin Auton Res       Date:  2015-03-20       Impact factor: 4.435

7.  Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.

Authors:  Amy C Arnold; Luis E Okamoto; Alfredo Gamboa; Bonnie K Black; Satish R Raj; Fernando Elijovich; David Robertson; Cyndya A Shibao; Italo Biaggioni
Journal:  Hypertension       Date:  2015-12-07       Impact factor: 10.190

Review 8.  Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease.

Authors:  Cyndya A Shibao; Horacio Kaufmann
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

9.  Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.

Authors:  Amy C Arnold; Luis E Okamoto; Alfredo Gamboa; Cyndya Shibao; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-12-24       Impact factor: 10.190

10.  Kidney atrophy vs hypertrophy in diabetes: which cells are involved?

Authors:  Samy L Habib
Journal:  Cell Cycle       Date:  2018-07-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.